UroGen Pharma (URGN) Tops Q3 EPS by 23c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to UroGen Pharma (URGN) Tops Q3 EPS by 23c

UPDATE: UroGen Pharma (URGN) Reports Exclusive License Agreement with Agenus (AGEN) to Advance Treatment of Urinary Tract Cancers

November 11, 2019 8:03 AM EST

(Updated - November 11, 2019 8:03 AM EST)

UroGen Pharma Ltd. (NASDAQ: URGN) today announced that it has entered into an exclusive worldwide1 license agreement with Agenus Inc (NASDAQ: AGEN) to develop and commercialize zalifrelimab (AGEN1884, anti-CTLA-4 antibody) via intravesical delivery in combination with UGN-201 for the treatment of urinary tract cancers. This combination is based on encouraging preclinical data utilizing UroGens proprietary sustained release technology, which is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option while... More